Investigating obesity induced gut microbiome changes in the development of multiple myeloma

背景：在英国，每年约有6,000人被诊断患有多发性骨髓瘤（MM）。目前骨髓瘤仍然无法治愈，中位生存率约为50%。MM是浆细胞的癌症，浆细胞被认为是适应性免疫系统的支柱，因为它们能够产生免疫球蛋白和对抗微生物感染。MM有许多相关的风险因素，然而，肥胖一直被认为是一个风险因素。在该项目中，通过获取MM患者的人体样本，本研究的目的是确定肥胖诱导的肠道微生物群变化对驱动/影响MM进展的作用。研究方法：更好地了解在其局部骨髓以及更广泛的器官系统背景下调节MM发展的机制，将使我们能够提出治疗干预策略。因此，本项目的目的是确定MM进展的代谢机制。具体来说，我们将确定肥胖引起的肠道微生物群变化在这些过程中的作用。

Background: Approximately 6,000 people are diagnosed with multiple myeloma (MM) in the UK each year. Presently myeloma remains incurable with a median survival of about 50%. MM is a cancer of plasma cells, which are considered the backbone of the adaptive immune system due to their ability to produce immunoglobulins and fight microbial infections. There are many associated risk factors for MM, however, obesity has consistently been recognized as a risk factor. In this project with access to human samples from MM patients, the aim of this study is to determine the role of obesity induced changes in gut microbiota on driving/influencing the progression of MM.Research methodology: Gaining a better understanding of the mechanisms regulating MM development in the context of its local bone marrow but also the wider organ system will enable us to propose strategies for therapeutic intervention. Therefore, the aim of this project is to define the metabolic mechanisms underpinning MM progression. Specifically, we will determine the role of changes in gut microbiota induced by obesity in these processes.